lobbying_activities: 3488766

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3488766	401ee552-0bb5-44b4-8573-5a32ee7fc7a0	Q4	MEHLMAN CONSULTING, INC.	284950	THE CAMPAIGN FOR SUSTAINABLE RX PRICING	2025	fourth_quarter	CPT	Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act. S. 2658 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.	HOUSE OF REPRESENTATIVES,SENATE	90000		0	0	2026-01-16T12:09:15-05:00